Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis

Journal of Pain Research

Volumn 11, Issue , 2018, Pages 151-164

  Birbara, Charles ^a   Dabezies, Eugene J ^b   Burr, Aimee M ^c   Fountaine, Robert J ^c   Smith, Michael D ^c   Brown, Mark T ^c   West, Christine R ^c   Arends, Rosalin H ^c   Verburg, Kenneth M ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Pensacola Research Consultants   (United States)

^c PFIZER INC   (United States)

Author keywords

Efficacy; Osteoarthritis; Safety; Subcutaneous; Tanezumab

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TANEZUMAB;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; GLOBAL ASSESSMENT OF FUNCTIONING; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; HYPESTHESIA; IMMUNOGENICITY; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; JOINT SWELLING; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NUMERIC RATING SCALE; PAIN; PAIN ASSESSMENT; PARALLEL DESIGN; PARESTHESIA; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN BURNING SENSATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERY ELDERLY; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

EID: 85041514144     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S135257     Document Type: Article

References (25)

1. Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189–204.
2. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27(2):85–91.
3. Walsh DA, McWilliams DF, Turley MJ, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford). 2010;49(10):1852–1861.
4. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs. 2008;22(6):349–359.
5. Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci. 2008;17(8):1326–1335.
6. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012; 13(8):790–798.
7. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013;65(7):1795–1803.
8. Ekman EF, Gimbel JS, Bello AE, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014; 41(11):2249–2259.
9. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363: 1521–1531.
10. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C; Tanezumab Investigators. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage. 2011;19(12):1405–1412.
11. Schnitzer TJ, Ekman EF, Spierings EL, et al. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015;74(6):1202–1211.
12. Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. 2011;19(6): 639–646.
13. Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013;154(9): 1603–1612.
14. Lalovic B, Xie R, Marshall S, Arends R. Population PK analysis of tanezumab administered to healthy volunteers subcutaneously or intravenously. Poster presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT); March 17–20, 2010; Atlanta, GA.
15. Xie R, Arends R, Olson S, Marshall S. Preliminary pharmacokinetic/ pharmacodynamic (PK/PD) analysis for the effect of tanezumab on overall daily pain score data in adults with moderate-to-severe pain due to osteoarthritis of the knee. Poster presented at: Population Approach Group in Europe (PAGE); June 23–26, 2009; St Petersburg, Russia.
16. Pfizer Inc. [home page on the Internet]. Tanezumab Arthritis Advisory Committee briefing document. NewYork, NY: Pfizer Inc.; 2012 [updated February 8, 2012]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Arthritis-DrugsAdvisoryCommittee/UCM295205.pdf. Accessed February 2, 2017.
17. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34(5):505–514.
18. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8): 1039–1049.
19. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494–502.
20. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–1840.
21. Stengaard-Pedersen K, Ekesbo R, Karvonen AL, Lyster M. Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing. Rheumatology (Oxford). 2004;43(5):592–595.
22. Pham T, van der Heijde D, Altman RD, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004;12(5):389–399.
23. Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23(Suppl 1):S18–S21.
24. Pfizer. Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study. Available from: https://clinicaltrials.gov/ct2/show/NCT01089725. NLM identifier NCT01089725. Accessed September 28, 2017.
25. Pfizer. A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections. Available from: https://clinicaltrials. gov/ct2/show/NCT00994890. NLM identifier NCT00994890. Accessed September 28, 2017.